MRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Mirati Therapeutics has the Momentum Rank of 0.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Mirati Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Jamie Christensen | officer: Sr. Vice President, Chief Scie | C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: EVP, Chief Commercial Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
Aaron Ondrey | officer: Interim CFO | 3545 CRAY COURT, SAN DIEGO CA 92121 |
Boxer Capital, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Christopher Fuglesang | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Shehan Bharatha Dissanayake | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Aaron I. Davis | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Mva Investors, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Boxer Asset Management Inc. | other: See remarks | CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000 |
Joseph Lewis | other: See remarks | PO BOX N7776, LYFORD BAHAMAS |
Faheem Hasnain | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John B Moriarty | officer: Chief Legal Officer | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Carol Giltner Gallagher | director | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Laurie Stelzer | officer: CFO | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Julie M Cherrington | director | 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus Research • 01-12-2024
By PRNewswire • 08-09-2023
By PRNewswire • 10-09-2023
By GuruFocus Research • 12-20-2023
By PRNewswire • 09-05-2023
By PRNewswire • 10-31-2023
By Marketwired • 10-09-2023
By PRNewswire • 01-10-2024
By PRNewswire • 08-23-2023
By PRNewswire • 09-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.